Cork-based biopharmaceutical company Evumed has announced a multi-million-euro investment to establish its European headquarters at Cork Airport Business Park, creating 30 high-value jobs across quality, regulatory, supply chain, finance and operational support functions during 2026. The investment further expands Cork’s role as a strategic centre for pharmaceutical manufacturing, life sciences operations and international healthcare innovation.

Cork Beo reported that the announcement was confirmed on 11 May 2026, with the new headquarters supporting Evumed’s plans to scale research, development and commercial activities across European markets. Founded in 2025, the company specialises in the development and delivery of generic, branded and biologic medicines, alongside pharmaceutical research and manufacturing operations.

The Cork headquarters will support a broad range of operational functions tied to compliance, product development, commercial coordination and supply chain management. The move also reflects increasing demand for integrated pharmaceutical infrastructure and specialist talent across Ireland’s life sciences sector.

The property letting was completed by Knight Frank, which said it is currently engaged in discussions with three additional multinational companies regarding prospective occupancy at the business park. The development highlights continued commercial interest in Cork’s business and logistics infrastructure.

Colm Moynihan, president of Evumed, said: “Cork Airport Business Park's exceptional global connectivity and modern infrastructure, coupled with Cork's position as a global hub for pharmaceutical manufacturing and innovation, offer Evumed the ideal location to grow as we aim to develop and deliver generic, branded, and biologic medicines.”

Cork Airport Business Park marked its 25th anniversary in 2025 and is home to major international occupiers including Amazon, IBM, McKesson, GSK and Red Hat.

Get the full details of Evumed's Cork HQ investment here.